ClinicalTrials.gg
CompletedNCT05822440Updated Oct 4, 2024Results posted

A Study to Learn About How Itraconazole Affects the Blood Level of Study Medicine (PF-07817883) in Healthy Adults.

A Phase 1 interventional study of PF-07817883 and Itraconazole in Healthy, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-04.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies in COVID-19 by Pfizer — 4 open to participants now, 10 under way, 3 of them phase 3. COVID-19 · Pfizer.

Enrollment
28th of 41
12 · median 20
Started
2023
with 11 others
Phase 1
25 of 69
none open now
Registered
39th of 69
by date

Among the 69 studies in COVID-19 by Pfizer, this one is the 28th largest by enrollment of the 41 interventional ones that give a count, is one of 12 that started in 2023, is one of 25 in phase 1, and was the 39th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 69 studies in COVID-19 by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in COVID-19 by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to learn how Itraconazole affects the blood level of PF-07817883 in Healthy Adults.

This study is seeking participants who are:

  • male and female aged 18 to 65 years old,
  • overtly healthy. This can be determined my medical evaluation, medical history, lab tests etc.

This study will consist of 2 parts, Period 1 and Period 2.

Period 1: participants will take PF-07817883 one time by mouth at the study clinic.

Period 2: participants will take PF-07817883 one time by mouth at the study clinic. They will also take daily itraconazole by mouth for 7 days.

Participants will stay at the study clinic for 2 weeks in total. The study doctors will collect blood and urine samples from everyone. The study doctors will check participants' reactions to the study medicine for safety measures. There is a follow-up call at 28 to 35 days from the last dose of PF-07817883.

Itraconazole is an approved medicine. It is also a metabolism inhibitor. When taken with some medicines, it affects the actual level of these medicines in the body. This study will compare blood levels of PF-07817883 given with and without Itraconazole. This will help decide safety and right amount for PF-07817883 when given with metabolism inhibitors.

Read the detailed description

This is a Phase 1, open-label, 2-period, fixed sequence study to estimate the effect of itraconazole, a strong CYP3A4 inhibitor, on the plasma PK of PF-07817883 in healthy adults. The study will consist of 2 treatments: a single oral dose of PF-07817883 alone and a single oral dose of PF-07817883 in combination with multiple oral doses of itraconazole. The PK and safety will be assessed and compared for single dose of PF-07817883 in period 1 and period 2.

03

Conditions studied

  • Healthy

Browse trials for

Keywords

  • COVID-19
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants aged 18 to 65 years of age, inclusive, at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and standard 12-lead .
  • of 17.5 to 32 kg/m2; and a total body weight >50 kg (110 lb).
  • Capable of giving signed .

Exclusion criteria

Exclusion Criteria:

  • Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality or other conditions that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, CV, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing) and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
  • Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).
  • Positive test result for SARS-CoV-2 infection at admission.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Period 1

    The treatment arm includes a single dose of PF-07817883 (Period 1 Day 1)

    Drug: PF-07817883

  • Experimental
    Period 2

    This treatment arm includes 7-day dosing of itraconazole with a single dose of PF-07817883 Co-administered on Day 4 (Period 2 Day 4)

    Drug: PF-07817883 · Drug: Itraconazole

Interventions

  • Single oral dose (period 1) or co-administered with itraconazole (period 2)

  • Interacting drug which will be given for 7 days in period 2

    Also known as: Sporanox®

06

What researchers measure

Primary outcomes

  1. Maximum Observed Concentration (Cmax) of PF-07817883

    Cmax was observed directly from data and measured in nanogram per milliliter (ng/mL).

    Time frame: Period 1: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose on Day 1; Period 2: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose on Day 4

  2. Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883

    AUCinf was derived by AUClast + (Clast\*/kel). AUClast was area under the plasma concentration-time profile from time 0 to the time of Clast; Clast\* was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the loglinear concentration-time curve. AUCinf was measured in nanogram\*hour per milliliter (ng\*hr/mL).

    Time frame: Period 1: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose on Day 1; Period 2: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose on Day 4

Secondary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious AE was any untoward medical occurrence at any dose that resulted in death; was life-threatening; required hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. TEAEs were events that occurred between first dose of study intervention and up to maximum of 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Day 1 of dosing up to 35 days post last dose of study intervention (maximum up to 48 days)

  2. Number of Participants With Laboratory Test Abnormalities

    Laboratory assessments included: hematology assessments included monocytes/leukocytes (percentage \[%\]) greater than (\>) 1.2\*upper limit of normal (ULN), urinalysis assessments included urine hemoglobin greater than or equal to (\>=) 1, low power field (LPF), urine bacteria \>20/LPF.

    Time frame: Day 1 of dosing up to last dose of study intervention or early termination/discontinuation (maximum up to 13 days)

  3. Number of Participants With Electrocardiogram (ECG) Findings Per Pre-defined Criteria

    Standard 12-lead ECGs was collected using an ECG system that automatically calculates the heart rate (HR) and measures PR interval, QT interval, QTcF, and QRS interval. All scheduled ECGs were performed after the participant had rested quietly for at least 5 minutes in a supine position. To ensure safety of the participants, a qualified individual at the investigator site made comparisons to baseline measurements. Pre-defined criteria was defined as 30 milliseconds (ms) less than (\<) change less than or equal to (\<=) 60 ms.

    Time frame: Day 1 of dosing up to last dose of study intervention or early termination/discontinuation (maximum up to 13 days)

  4. Number of Participants With Vital Signs Findings Per Pre-defined Criteria

    Vital signs included: supine diastolic blood pressure (DBP) measured in millimetre of mercury (mmHg) with criteria value as follows- Value \<50 mmHg, change\>= 20 mmHg increase, change \>= 20 mmHg decrease; supine pulse rate (PR) measured in beats per minute (bpm) with criteria values as follows- value \< 40 bpm, value \> 120 bpm; supine systolic blood pressure (SBP, mmHg) with criteria values as follows- value\< 90 mmHg, change \>= 30 mmHg increase, change \>=30 mmHg decrease. Vital signs (SBP BP, and pulse rate) were measured with participants after having a rest for at least 5 minutes in a supine position. Supine BP was measured with the participant's arm supported at the level of the heart and recorded to the nearest mmHg after approximately 5 minutes of rest. If timing of these measurements coincided with a blood collection, BP and PR were obtained prior to nominal time of blood collection. Only participants having at least 1 vital sign findings per pre-defined criteria are reported.

    Time frame: Day 1 of dosing up to last dose of study intervention or early termination/discontinuation (maximum up to 13 days)

  5. Number of Participants With Clinically Significant Abnormalities in Physical Examination

    A complete physical examination included, at a minimum, head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, and gastrointestinal, musculoskeletal, and neurological systems. A brief physical examination included, at a minimum, assessments of general appearance, the respiratory and CV systems, and participant-reported symptoms. Physical examinations were conducted by a physician, trained physician's assistant, or nurse practitioner as acceptable according to local regulation. Clinical significance of physical examination abnormalities was judged by physicians.

    Time frame: Day 1 of dosing up to last dose of study intervention or early termination/discontinuation (maximum up to 13 days)

  6. Time to Reach Cmax (Tmax) of PF-07817883

    Tmax is the time taken (in hours) to reach the maximum serum drug concentration. Tmax was observed directly from data as time of first occurrence.

    Time frame: Period 1: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose on Day 1; Period 2: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose on Day 4

  7. Terminal Phase Half-Life (t1/2) of PF-07817883

    Terminal half-life was defined as the time measured for the plasma concentration of drug to decrease by one half. t1/2 was determined by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the loglinear concentration-time curve.

    Time frame: Period 1: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose on Day 1; Period 2: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose on Day 4

  8. Apparent Clearance (CL/F) of PF-07817883

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose administered divided by area under the concentration curve from time 0 extrapolated to infinite time (AUCinf).

    Time frame: Period 1: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose on Day 1; Period 2: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose on Day 4

  9. Apparent Volume of Distribution (Vz/F) of PF-07817883

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.

    Time frame: Period 1: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose on Day 1; Period 2: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose on Day 4

07

Results

Posted Oct 4, 2024

Participant flow

Treatment Period 1 (5 Days)
Participant flow — Treatment Period 1 (5 Days)
MilestonePF-07817883PF-07817883 + Itraconazole
Started120
Completed120
Not completed00
Treatment Period 2 (8 Days)
Participant flow — Treatment Period 2 (8 Days)
MilestonePF-07817883PF-07817883 + Itraconazole
Started012
Completed012
Not completed00

Outcome measures

PrimaryMaximum Observed Concentration (Cmax) of PF-07817883

Cmax was observed directly from data and measured in nanogram per milliliter (ng/mL).

Time frame:
Period 1: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose on Day 1; Period 2: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose on Day 4
Reported as:
Geometric mean · ng/mL
Maximum Observed Concentration (Cmax) of PF-07817883
ng/mLPF-07817883PF-07817883 + Itraconazole
Maximum Observed Concentration (Cmax) of PF-078178834030 ± 284985 ± 41
Statistical analysis
  • PF-07817883 vs PF-07817883 + Itraconazole · Ratio of adjusted geometric means: 124.35 · 90% CI 100.22 to 154.29
PrimaryArea Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883

AUCinf was derived by AUClast + (Clast\*/kel). AUClast was area under the plasma concentration-time profile from time 0 to the time of Clast; Clast\* was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the loglinear concentration-time curve. AUCinf was measured in nanogram\*hour per milliliter (ng\*hr/mL).

Time frame:
Period 1: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose on Day 1; Period 2: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose on Day 4
Reported as:
Geometric mean · ng*hr/mL
Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883
ng*hr/mLPF-07817883PF-07817883 + Itraconazole
Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-0781788321720 ± 2646400 ± 36
Statistical analysis
  • PF-07817883 vs PF-07817883 + Itraconazole · Ratio of adjusted geometric means: 212.83 · 90% CI 183.76 to 246.50
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious AE was any untoward medical occurrence at any dose that resulted in death; was life-threatening; required hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. TEAEs were events that occurred between first dose of study intervention and up to maximum of 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Day 1 of dosing up to 35 days post last dose of study intervention (maximum up to 48 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsPF-07817883ItraconazoleItraconazole + PF-07817883
Number of Participants With Treatment Emergent Adverse Events (TEAEs)132
SecondaryNumber of Participants With Laboratory Test Abnormalities

Laboratory assessments included: hematology assessments included monocytes/leukocytes (percentage \[%\]) greater than (\>) 1.2\*upper limit of normal (ULN), urinalysis assessments included urine hemoglobin greater than or equal to (\>=) 1, low power field (LPF), urine bacteria \>20/LPF.

Time frame:
Day 1 of dosing up to last dose of study intervention or early termination/discontinuation (maximum up to 13 days)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities
ParticipantsPF-07817883PF-07817883 + Itraconazole
Number of Participants With Laboratory Test Abnormalities03
SecondaryNumber of Participants With Electrocardiogram (ECG) Findings Per Pre-defined Criteria

Standard 12-lead ECGs was collected using an ECG system that automatically calculates the heart rate (HR) and measures PR interval, QT interval, QTcF, and QRS interval. All scheduled ECGs were performed after the participant had rested quietly for at least 5 minutes in a supine position. To ensure safety of the participants, a qualified individual at the investigator site made comparisons to baseline measurements. Pre-defined criteria was defined as 30 milliseconds (ms) less than (\<) change less than or equal to (\<=) 60 ms.

Time frame:
Day 1 of dosing up to last dose of study intervention or early termination/discontinuation (maximum up to 13 days)
Reported as:
Count of participants · Participants
Number of Participants With Electrocardiogram (ECG) Findings Per Pre-defined Criteria
ParticipantsPF-07817883PF-07817883 + Itraconazole
Number of Participants With Electrocardiogram (ECG) Findings Per Pre-defined Criteria01
SecondaryNumber of Participants With Vital Signs Findings Per Pre-defined Criteria

Vital signs included: supine diastolic blood pressure (DBP) measured in millimetre of mercury (mmHg) with criteria value as follows- Value \<50 mmHg, change\>= 20 mmHg increase, change \>= 20 mmHg decrease; supine pulse rate (PR) measured in beats per minute (bpm) with criteria values as follows- value \< 40 bpm, value \> 120 bpm; supine systolic blood pressure (SBP, mmHg) with criteria values as follows- value\< 90 mmHg, change \>= 30 mmHg increase, change \>=30 mmHg decrease. Vital signs (SBP BP, and pulse rate) were measured with participants after having a rest for at least 5 minutes in a supine position. Supine BP was measured with the participant's arm supported at the level of the heart and recorded to the nearest mmHg after approximately 5 minutes of rest. If timing of these measurements coincided with a blood collection, BP and PR were obtained prior to nominal time of blood collection. Only participants having at least 1 vital sign findings per pre-defined criteria are reported.

Time frame:
Day 1 of dosing up to last dose of study intervention or early termination/discontinuation (maximum up to 13 days)
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs Findings Per Pre-defined Criteria
ParticipantsPF-07817883PF-07817883 + Itraconazole
Number of Participants With Vital Signs Findings Per Pre-defined Criteria01
SecondaryNumber of Participants With Clinically Significant Abnormalities in Physical Examination

A complete physical examination included, at a minimum, head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, and gastrointestinal, musculoskeletal, and neurological systems. A brief physical examination included, at a minimum, assessments of general appearance, the respiratory and CV systems, and participant-reported symptoms. Physical examinations were conducted by a physician, trained physician's assistant, or nurse practitioner as acceptable according to local regulation. Clinical significance of physical examination abnormalities was judged by physicians.

Time frame:
Day 1 of dosing up to last dose of study intervention or early termination/discontinuation (maximum up to 13 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Physical Examination
ParticipantsPF-07817883PF-07817883 + Itraconazole
Number of Participants With Clinically Significant Abnormalities in Physical Examination00
SecondaryTime to Reach Cmax (Tmax) of PF-07817883

Tmax is the time taken (in hours) to reach the maximum serum drug concentration. Tmax was observed directly from data as time of first occurrence.

Time frame:
Period 1: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose on Day 1; Period 2: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose on Day 4
Reported as:
Median · Hours
Time to Reach Cmax (Tmax) of PF-07817883
HoursPF-07817883PF-07817883 + Itraconazole
Time to Reach Cmax (Tmax) of PF-078178831.76 (0.517 to 4.03)2.00 (1.52 to 4.00)
SecondaryTerminal Phase Half-Life (t1/2) of PF-07817883

Terminal half-life was defined as the time measured for the plasma concentration of drug to decrease by one half. t1/2 was determined by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the loglinear concentration-time curve.

Time frame:
Period 1: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose on Day 1; Period 2: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose on Day 4
Reported as:
Mean · Hours
Terminal Phase Half-Life (t1/2) of PF-07817883
HoursPF-07817883PF-07817883 + Itraconazole
Terminal Phase Half-Life (t1/2) of PF-078178835.502 ± 2.370310.92 ± 8.3667
SecondaryApparent Clearance (CL/F) of PF-07817883

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose administered divided by area under the concentration curve from time 0 extrapolated to infinite time (AUCinf).

Time frame:
Period 1: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose on Day 1; Period 2: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose on Day 4
Reported as:
Geometric mean · Liter/Hours
Apparent Clearance (CL/F) of PF-07817883
Liter/HoursPF-07817883PF-07817883 + Itraconazole
Apparent Clearance (CL/F) of PF-0781788313.81 ± 266.469 ± 36
SecondaryApparent Volume of Distribution (Vz/F) of PF-07817883

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.

Time frame:
Period 1: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose on Day 1; Period 2: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose on Day 4
Reported as:
Geometric mean · Liter
Apparent Volume of Distribution (Vz/F) of PF-07817883
LiterPF-07817883PF-07817883 + Itraconazole
Apparent Volume of Distribution (Vz/F) of PF-07817883100.4 ± 6386.29 ± 51

Adverse events

Collected over Day 1 up to 35 days after last dose of study drug (maximum up to 48 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-078178830/12 (0%)0/12 (0%)1/12 (8.3%)
Itraconazole0/12 (0%)0/12 (0%)3/12 (25%)
Itraconazole + PF-078178830/12 (0%)0/12 (0%)2/12 (16.7%)
Most frequent other events
Most frequent other events
EventPF-07817883ItraconazoleItraconazole + PF-07817883
Abdominal distensionGastrointestinal disorders1/120/120/12
DiarrhoeaGastrointestinal disorders1/121/120/12
Mouth haemorrhageGastrointestinal disorders0/120/121/12
NauseaGastrointestinal disorders0/120/121/12
VomitingGastrointestinal disorders0/121/121/12
Feeling hotGeneral disorders0/121/120/12
DizzinessNervous system disorders0/120/121/12
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/120/121/12
Ingrown hairSkin and subcutaneous tissue disorders0/120/121/12

Baseline characteristics

All participants who were enrolled in the study.

Age, Continuous
Age, Continuous(Years)All Participants
Mean38.7 ± 8.48
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female4
Male8
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants
Hispanic or Latino2
Not Hispanic or Latino10
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
American Indian or Alaska Native1
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American6
White4
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • New Haven Clinical Research Unit
    New Haven, Connecticut 06511, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Jul 2023, 2 months.

Results were first posted in Oct 2024, 1 year 2 months after primary completion.

Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's 2 months is below that.

Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2023
First posted
Apr 20, 2023
StartActual
Apr 13, 2023
Primary completionActual
Jul 10, 2023
CompletionActual
Jul 10, 2023
Results first posted
Oct 4, 2024
Last update
Oct 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05822440
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 20, 2023
Start date
Apr 13, 2023
Primary completion
Jul 10, 2023
Completion
Jul 10, 2023
Results posted
Oct 4, 2024
Last update
Oct 4, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuzatrelvir

Start the discussion